Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis.
Audrey GauthierSebastien VielMagali PerretGuillaume BrocardRomain CaseyChristine LombardSabine Laurent-ChabalierMarc DebouverieGilles EdanSandra VukusicChristine Lebrun-FrénayJérôme De SèzeDavid Axel LaplaudGiovanni CastelnovoOlivier GoutAurélie RuetThibault MoreauOlivier CasezPierre ClavelouEric BergerHélène ZephirSophie Trouillet-AssantEric Thouvenotnull nullPublished in: Annals of clinical and translational neurology (2021)
We compared SimoaTM and EllaTM immunoassays to assess serum neurofilament-light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The EllaTM instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to EllaTM results. As for SimoaTM , serum neurofilament-light chain levels measured by EllaTM were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.